News

Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) announced today that Optune Lua® has received a CE (Conformité Européenne) Mark for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) ...
Seeking Alpha4d
Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer
“Optune Lua is an innovative and urgently needed new approach for treating metastatic non-small cell lung cancer,” said Joachim Aerts, M.D., a LUNAR investigator and Professor of Pulmonary ...
CURE3d
Optune Lua Receives CE Mark in Europe for Metastatic NSCLC
Optune Lua received a CE Mark for metastatic non–small cell lung cancer with immune checkpoint inhibitors or docetaxel.
Breast cancer drug Supinoxin shows potential for small-cell lung cancer in new tests
Purdue University scientists have identified the Supinoxin small-molecule drug as a possible new therapy for small-cell lung ...
Innovent Announces NMPA Approval Of Limertinib, A Third-Generation EGFR TKI Collaborated With ASK Pharma, For The First-Line Treatment Of Lung Cancer
SAN FRANCISCO and SUZHOU,China, April 25, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company t ...
CURE5d
Enhertu Combo Improves Progression in HER2+ Metastatic Breast Cancer
Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive ...
MassDevice4d
Novocure wins CE mark for its lung cancer treatment wearable
The regulatory approval in the EU comes approximately six months after Novocure secured FDA approval of the system.